Announced details
We are working with the Center to prepare for the start of the Phase 1b monzosertib trial led by the Center. The disclosure states that an MOU was executed on 18 December 2025.
The University of Texas MD Anderson Cancer Center in the United States. Other information on its location, representative, capital, year established and business activities is Not disclosed.
ClinicalTrials.gov ID: NCT07780565. The validity period is Not disclosed.
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
ClinicalTrials.gov
| Item | Details |
|---|---|
| Names of Products / Services Covered | monzosertib（AS-0141） |
| Counterparty | The University of Texas MD Anderson Cancer Center |
| Counterparty overview | The University of Texas MD Anderson Cancer Center in the United States. Other information on its location, representative, capital, year established and business activities is Not disclosed. |
| Relationship with the Company | We are working with the Center to prepare for the start of the Phase 1b monzosertib trial led by the Center. The disclosure states that an MOU was executed on 18 December 2025. |
| Contract Date | 18 December 2025 (the date on which execution of the MOU was announced; the date the MOU itself was executed is Not disclosed) |
| Applicable area | Relapsed/refractory acute myeloid leukemia (AML), High-risk myelodysplastic syndromes (MDS) |
| Registration number and expiry date | ClinicalTrials.gov ID: NCT07780565. The validity period is Not disclosed. |
| Source | ClinicalTrials.gov |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To indicate progress in preparations for initiating this Phase 1b trial.